Spero
Spero Inc. is a South Korea-based clinical research organization founded in 2022 that delivers decentralized clinical trial services and integrated CRO technology (eConsent, ePRO, centralized monitoring, patient recruitment) to pharmaceutical and biotech sponsors.
- Company typePrivate
- Founded2022
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Spero does
Spero Inc. (스페로(주)) is a South Korea-based clinical research organization (CRO) founded in 2022 that provides decentralized clinical trial (DCT) services and integrated clinical trial management solutions to pharmaceutical and biotech sponsors. The firm operates a platform-plus-modules architecture centered on its proprietary iSPERO / SPERO DCT platform, supplemented by cubeCONSENT 3.0 for electronic informed consent, VIA/cubeRBQM for centralized monitoring and risk-based quality management (120+ default KRIs with EDC integration), ePRO for electronic patient-reported outcomes, and MediCLEO for patient recruitment (140+ studies delivered). It also delivers a full-service CRO suite covering medical writing, project management, study start-up, site management and monitoring, data management, biostatistics, quality assurance, centralized monitoring and consulting.
Spero runs on a professional services / managed services revenue model with custom quotation, multi-year enterprise contracts, and sales-led B2B direct engagement — typically responding to clinical trial inquiries within 24 business hours via dedicated contact channels ([email protected] and [email protected]). Its core technology partnership with CRScube Inc. provides cubeCDMS (clinical data management system) and cubeCONSENT 3.0, with VIA/cubeRBQM offering interlocking integration with cubeCDMS and broader EDC system data import.
The company targets the Korean clinical trial market primarily, evidenced by MFDS-focused regulatory positioning, Korean-language website, KoNECT-MOHW-MFDS and MFDS/KSCD conference participation, and KIC Exhibition presence. AWS infrastructure was migrated to Japan and Singapore regions in September 2023, suggesting preparation for cross-border trial operations. Marketing is concentrated in content-led channels: website, annual webinars, industry conferences, a SPERO NEWS newsletter and a published resource library including MFDS electronic consent Q&A documentation. No disclosed funding rounds, named customers, or revenue figures were identified in the available sources.
Spero firmographics
Firmographics- Name
- Spero
- Legal name
- Spero Inc. (스페로(주))
- Website
- https://ispero.io
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Spero Inc. is a South Korea-based clinical research organization founded in 2022 that delivers decentralized clinical trial services and integrated CRO technology (eConsent, ePRO, centralized monitoring, patient recruitment) to pharmaceutical and biotech sponsors.
- Ownership category
- akta.pro rank
Spero industry classification
Industry- Product category
- Clinical Research Organization (CRO) / Decentralized Clinical Trial Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industry
- Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)
Keywords
Where Spero is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Spero business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Clinical Development Services: Full-service CRO offerings including Medical Writing, Project Management, Study Start-Up, Site Management & Monitoring, Data Management, Biostatistics, Quality Assurance, Centralized Monitoring, and Consulting Services. Provided on a project/contract basis to pharmaceutical and biotech sponsors.
- Clinical Trial Solutions: Technology-enabled solutions including DCT platform access, eConsent, ePRO, patient recruitment services (MediCLEO), and centralized monitoring (VIA/cubeRBQM). Sold as integrated service packages to clinical trial sponsors.
- Clinical Trial Consultation: Consulting services for clinical trial operations, decentralized clinical trials, centralized monitoring, and patient recruitment. Provided through direct inquiry and consultation requests.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom quotation based on project scope |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Spero product offering
Product offeringCore offering
Spero is a clinical research organization that delivers integrated decentralized clinical trial (DCT) solutions to pharmaceutical and biotech sponsors. It combines traditional clinical development services (medical writing, project management, study start-up, site management and monitoring, data management, biostatistics, quality assurance, centralized monitoring, and consulting) with proprietary digital tools including the iSPERO DCT platform, VIA/cubeRBQM centralized monitoring, cubeCONSENT 3.0 electronic consent, ePRO, and the MediCLEO patient recruitment service.
Product overview
Spero is a dedicated Decentralized Clinical Trial (DCT) CRO providing integrated clinical trial solutions. The company operates a platform-plus-modules architecture combining a proprietary decentralized clinical trial platform (SPERO DCT / iSPERO) with specialized add-on solutions including VIA/cubeRBQM for centralized monitoring and risk-based quality management, cubeCONSENT 3.0 for electronic informed consent, ePRO for patient-reported outcomes, and MediCLEO for patient recruitment. Supporting these digital solutions is a comprehensive suite of clinical development services covering Medical Writing, Project Management, Study Start-Up, Site Management & Monitoring, Data Management, Biostatistics, Quality Assurance, Centralized Monitoring, and Consulting. The portfolio enables hybrid digital clinical trials that integrate traditional site-based operations with decentralized elements for improved participant convenience and data quality.
Differentiator
Problem solved
Functional benefit
Brands
- iSPERO: Decentralized clinical trial platform
- cubeCONSENT 3.0
- VIA/cubeRBQM
- MediCLEO
Products and services
- SPERO DCT (iSPERO)
- VIA / cubeRBQM
- MediCLEO
- cubeCONSENT 3.0
- ePRO (Electronic Patient-Reported Outcome)
- Medical Writing
- Project Management
- Study Start-Up
- Site Management & Monitoring
- Data Management
- Biostatistics
- Quality Assurance
- Centralized Monitoring (service)
- Consulting Service
Quantifiable outcome
- MediCLEO patient recruitment service has completed over 140 clinical studies
Companies that use Spero
Customer profileSegments2 records
Ideal customer profiles1 record
Spero technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature6 records
Spero partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- CRScube Inc. (주)씨알에스큐브coreCRScube is a technology partner providing cubeCDMS (clinical data management system) and cubeCONSENT 3.0 electronic consent solution. Spero's VIA centralized monitoring solution has interlocking integration with cubeCDMS. The companies collaborate on DCT solutions with cubeCONSENT supporting electronic informed consent procedures integrated with Spero's clinical trial services.
- CRScube Inc. (주)씨알에스큐브coreCRScube provides cloud server and web hosting services to Spero under a data processing delegation agreement. Services include customer support, technical measures for personal information safety including access control, encryption, and security program updates. Partnership supports Spero's digital infrastructure for clinical trial operations.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Spero competitors and assessment
Company assessmentBroad incumbents
- IQVIA: Global full-service CRO and clinical technology provider with extensive DCT capabilities through the IQVIA Decentralized Clinical Trials platform. Highly relevant as a broad incumbent that competes for the same pharma/biotech sponsors Spero targets, albeit at vastly larger scale.
- Parexel: Large global CRO offering full-service clinical development plus decentralized and patient-centric trial solutions. Overlaps with Spero's CRO service portfolio (medical writing, monitoring, biostatistics, data management) for pharma and biotech sponsors.
- Medidata Solutions: Clinical trial technology platform (Rave EDC, eCOA, eConsent, RBQM) widely used by sponsors and CROs. Direct overlap with Spero's iSPERO DCT platform, ePRO, eConsent, and VIA/cubeRBQM functionality, though Medidata is primarily a software provider serving many CROs.
- Fortrea: Spin-off of Labcorp's clinical development business, providing full-service CRO services including decentralized trial enablement. Overlaps with Spero's full-service CRO portfolio (PM, monitoring, biostatistics, DM) at larger global scale.
- Oracle Health Sciences: Provider of EDC (Oracle Clinical One), eClinical platform, and clinical trial analytics used by sponsors and CROs. Competes with Spero's data management, EDC integration, and centralized monitoring capabilities.
Direct peers
- Medable: Dedicated decentralized clinical trial platform offering eConsent, eCOA, telehealth, and patient experience modules. Closely comparable to Spero's iSPERO stack in product scope and target customer (pharma/biotech sponsors running DCT and hybrid trials).
- Science 37: DCT-native CRO and platform provider offering unified trial orchestration, eConsent, eCOA, and decentralized site services. Directly comparable to Spero's integrated CRO + DCT platform model.
- Clario: Clinical trial endpoint technology and decentralized trial solutions provider with eCOA, medical imaging, and RBQM capabilities. Directly comparable to Spero's ePRO and centralized monitoring modules within a DCT offering.
Emerging players
- CRScube: Korean clinical trial technology provider whose cubeCDMS, cubeCONSENT 3.0, and hosting services are integrated into Spero's iSPERO and VIA offerings. Adjacent competitor and partner in the Korean DCT ecosystem with overlapping DM and eConsent capabilities.
- Curebase: DCT-focused clinical trial platform and provider offering eConsent, eCOA, remote monitoring, and a hybrid CRO service model. Comparable emerging peer with overlapping product modules and a similar SMB-CRO positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Spero social profiles
Digital presenceSpero financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spero leadership team
Management profileNumber of profiles
Profiles1 record
Spero funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spero M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spero
What does Spero do?
Spero is a clinical research organization that delivers integrated decentralized clinical trial (DCT) solutions to pharmaceutical and biotech sponsors. It combines traditional clinical development services (medical writing, project management, study start-up, site management and monitoring, data management, biostatistics, quality assurance, centralized monitoring, and consulting) with proprietary digital tools including the iSPERO DCT platform, VIA/cubeRBQM centralized monitoring, cubeCONSENT 3.0 electronic consent, ePRO, and the MediCLEO patient recruitment service.
Is Spero a public or private company?
Spero is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Spero founded?
Spero was founded in 2022. It employs 11 to 50 people.
Where is Spero based?
Spero is headquartered in Seoul, South Korea, in the Asia region.
How does Spero make money?
Three revenue lines are on record. Clinical Development Services are the primary driver. The others are clinical Trial Solutions and clinical Trial Consultation.
Who are Spero's main competitors?
Broad incumbents on record are IQVIA, Parexel, Medidata Solutions, Fortrea and Oracle Health Sciences. Direct peers are Medable, Science 37 and Clario. Emerging players are CRScube and Curebase.
Does Spero have an API?
No public API is recorded for Spero.
What industry is Spero in?
Spero's product category is Clinical Research Organization (CRO) / Decentralized Clinical Trial Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAEAK, Point-of-Care & Decentralized Trial Testing Services. Its NAICS code is 541715 and its SIC code is 8731.